Protalix BioTherapeutics, Inc. Common Stock (PLX)
Protalix BioTherapeutics, Inc. is an Israeli biopharmaceutical company specializing in the development and commercialization of plant cell-based recombinant protein production technology. The company's technology platform aims to create cost-effective and scalable treatments for rare and ultra-rare orphan diseases. Protalix is known for its focus on enzyme replacement therapies and has developed products such as taliglucerase alfa for Gaucher disease.
Company News
The global Fabry disease treatment market is expected to grow from $2.76 billion in 2024 to $7.02 billion by 2034, at a CAGR of 9.8%. Key factors driving the market include FDA clearance of Fabry disease drugs and increased R&D investment.
The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider tran...
Shares of Israeli pharmaceutical giant Teva are down Monday following Hamas's attack over the weekend.
Penny stocks to watch under $5 The post Top Penny Stocks To Buy? 4 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.